REALIsM-HF Pilot Study

Heart Failure Clinical Trial

— REALIsM-HF  

Official title:

Real Life Multimarker Monitoring in Patients With Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03507439
• Other study ID #: 19167
• Status: Completed
• Phase: N/A
• Start date: April 6, 2018
• Est. completion date: March 12, 2021

Study information

• Verified date: July 2022
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart failure and reduced ejection fraction (HFrEF). It aims to identify potential novel endpoints for future heart failure trials by exploring clinically relevant changes over time and correlations/associations with conventional endpoints such as the six minute walking distance (6MWD), biomarkers and clinical events. Furthermore, it aims to address the challenges and feasibility of implementing device based measurements under real-life conditions.

Description:

Device 1 AVIVO Mobile Patient Management System (Medtronic USA), substituted by VitalPatch biosensor (VitalConnect USA) during the course of the study Device 2 DynaPort Move Monitor (McRoberts, NL)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: March 12, 2021
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent signed before any study-specific procedure

• Men or women aged 45 years and older

• Established diagnosis of chronic heart failure NYHA class II-IV

• Worsening heart failure requiring hospitalization for the initiation of intensification of heart failure therapy with at least one of the following: a) BNP = 100 pg/mL or NT-proBNP = 400 pg/mL (sinus rhythm) OR BNP = 300 pg/mL or NT-proBNP = 1200 pg/mL (atrial fibrillation); OR b) Radiographic evidence of pulmonary congestion (interstitial edema, pulmonary venous hypertension, vascular congestion, pleural effusion); OR c) Catheterization documented elevated filling pressures at rest (left ventricular end-diastolic pressure =15 mmHg or pulmonary capillary wedge pressure = 20 mmHg) or with exercise (pulmonary capillary wedge pressure = 25 mmHg) OR Ambulatory patients with a history of heart failure on individually optimized treatment with HF medications unless contraindicated or not tolerated, for at least 12 weeks and at least one of the following: a) Hospitalization for heart failure within the past 12 months; OR b) BNP = 100 pg/mL or NT-proBNP = 400 pg/mL (sinus rhythm) or BNP = 300 pg/mL or NT-proBNP = 1200 pg/mL (atrial fibrillation)

• For HFrEF only: EF =35% assessed by any imaging modality (e.g. echocardiography, cardiac magnetic resonance, cine levocardiography) within 12 months prior to study inclusion

• For HFpEF only: EF =45% assessed by any imaging modality (e.g. echocardiography, cardiac magnetic resonance, cine levocardiography) within 12 months prior to study inclusion

• Willingness to wear the DynaPort Move Monitor accelerometer belt and VitalPatch Biosensor during the trial

• Body size allows wearing of the accelerometer belt as confirmed by ability to comfortably fasten the test belt provided for the screening process

Exclusion Criteria

• Inability to comply with planned study procedures or to comply with study protocol requirements; this includes completing required data collection, and attending required follow up study visits

• Hemoglobin < 8.0 g/dl

• Acute coronary syndrome or percutaneous coronary intervention within 3 months prior to informed consent

• Listing for heart transplantation and / or anticipated implantation of a ventricular assist device

• Inability to exercise: wheelchair / scooter / walker dependent; dependent on supplemental oxygen

• Known clinically significant persistent coronary ischemia (based on medical history, a preexisting or a recent clinical stress test)

• HF is not the primary factor limiting activity within the last three months as indicated by the patient affirming #1, #2 or #3 of the following questionnaire: My ability to be active is most limited by: #1 - Joint, foot, leg, hip or back pain; #2 - Unsteadiness or dizziness impairing daily mobility; #3 - Lifestyle, weather, or I just don't like to be active

• Occurrence of any of the following within 3 months prior to informed consent:

Myocardial infarction, Hospitalization for unstable angina, Stroke or transient ischemic attack, Coronary artery bypass graft (CABG), Percutaneous coronary intervention (PCI), Implantation of a cardiac resynchronization therapy device (CRTD), Major surgery (that could interfere with patients' ability to exercise)

• PCI, CABG or implantation of a CRTD planned between randomization and Visit 4

• Subject who cannot tolerate placement of external patch monitor on chest in the proposed location (ECG lead II orientation)

• Subject with known allergies or hypersensitivities to adhesives or hydrogels

• Severe uncorrected valvular heart disease

• Known clinically relevant ventricular arrhythmias (sustained ventricular tachycardia, ventricular flutter or fibrillation)

• Severe pulmonary disease with any of the following: Requirement of continuous (home) oxygen or History of chronic obstructive pulmonary disease = GOLD III

• Previous (within 30 days or 5 half-lives of the investigational drug, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s)

• Any condition or therapy, which would make the patient unsuitable for the study, or life expectancy less than 12 months (e.g. active malignancy)

• Heavy alcohol consumption or the use of illicit drugs that, in the opinion of the investigator, may interfere with the patient's safety and / or compliance

• Patients who regularly (> 1x per week) swim, do water aerobics or go to the sauna, unwilling to omit this activity while needing to wear the study specific medical devices

• Active myocarditis

• Primary hypertrophic cardiomyopathy

• Constrictive pericarditis or pericardial tamponade

• Close affiliation with the investigational site, e.g. a close relative of the investigator, dependent person (e.g. employee or student of the investigational site)

• Previous participate in the study

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• AVIVO Mobile Patient Management (MPM) System
Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
• VitalPatch biosensor
Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
• DynaPort Move Monitor
Wearable device for ambulatory monitoring of physical activity, used by participants for 2 monitoring periods of 7 days each in the study

Locations

Country	Name	City	State
Germany	Charité - Campus Virchow-Klinikum (CVK)	Berlin
Germany	Heinrich-Heine-Universität Düsseldorf	Düsseldorf	Nordrhein-Westfalen
Germany	Universitätsklinikum Köln	Köln	Nordrhein-Westfalen
Italy	ASST Spedali Civili di Brescia	Brescia	Lombardia
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

United States,  Germany,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants With Adverse Events	An adverse event (AE) was any untoward medical occurrence in a participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal product. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly and another medical important serious event as judged by the investigator.	From signing the ICF until follow-up visit (up to 7 months)
Primary	Daily Steps Count	Daily steps count was measured with DynaPort Move Monitor device and evaluated to reflect the amount of daily physical activity.	At Day 9 and Day 77
Primary	Daily Physical Activity Level	Movement intensity of an activity, which was the average body acceleration (g) during this activity, was measured with DynaPort Move Monitor device and evaluated as daily physical activity level (PAL). Higher values indicate higher physical activity level and intensity.	At Day 9 and Day 77
Primary	Total Daily Energy Expenditure	Total daily energy expenditure was measured with DynaPort Move Monitor device and evaluated to reflect the amount of daily physical activity.	At Day 9 and Day 77
Primary	Duration of Daily Physical Activity	Duration of daily physical activity was measured with DynaPort Move Monitor device.	At Day 9 and Day 77
Primary	Time Duration Per Activity Status	Time duration per activity status was measured with DynaPort Move Monitor device and evaluated to reflect the intensity of daily physical activity. Physical Activity intensities use absolute aerobic intensity in terms of Metabolic Equivalent of Task (MET), which is a physiological concept expressing the energy cost of a physical activity as a multiple of Basal Metabolic Rate (BMR). By convention, 1 MET is considered as the resting metabolic rate obtained during quiet sitting. According to the American College of Sports Medicine (ACSM) thresholds for adults: Light-intensity activities are defined as 1.1 MET to 2.9 METs; Moderate-intensity activities are defined as 3.0 to 5.9 METs; Vigorous-intensity activities are defined as 6.0 METs or more.	At Day 9 and Day 77
Primary	Amount of Daily Physical Activity Measured With VitalPatch Biosensor	Amount of daily physical activity was collected and measured with VitalPatch biosensor.	Up to Day 84
Primary	Duration of Daily Physical Activity Measured With VitalPatch Biosensor	Duration of daily physical activity was collected and measured with VitalPatch biosensor.	Up to Day 84
Primary	Intensity of Daily Physical Activity Measured With VitalPatch Biosensor	Intensity of daily physical activity was collected and measured with VitalPatch biosensor.	Up to Day 84
Secondary	6-minute Walking Distance (6MWD)	6-minute walking distance (6MWD) is a exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. An increase in the distance walked indicates improvement in basic mobility.	At Day 84
Secondary	Sleep Movements	Sleep movements was measured with DynaPort Move Monitor device.	Up to Day 84
Secondary	Sleep Patterns	Sleep patterns was measured with DynaPort Move Monitor device.	Up to Day 84
Secondary	Sit-to-stand Behaviour	Sit-to-stand behaviour was measured with DynaPort Move Monitor device.	Up to Day 84
Secondary	Quality of Life as Measured With the Kansas City Cardiomyopathy Questionnaire Score	The Kansas City Cardiomyopathy Questionnaire (KCCQ) is the leading health-related quality-of-life measure for patients with heart failure (HF). It is a 23-item questionnaire that independently measures the impact of patients' HF, or its treatment, on 7 distinct domains: symptom frequency, symptom burden, physical limitation, quality of life, social limitations, self-efficacy and symptoms stability. Physical Limitation ranges 0-100. Total Symptom Score (range 0-100) combines the Symptom Frequency and the Symptom Burden scores; Clinical Summary Score (range 0-100) combines the Total Symptom and Physical Limitation scores to replicate the NYHA classification; Overall Summary Score (range 0-100) includes the Total Symptom, Physical Limitation, Social Limitations, and Quality of Life scores. Higher scores indicate more favorable states.	At Day 9 and Day 84
Secondary	Quality of Life as Measured With the PRO - Activity Scores	REALIsM-HF exploratory daily questionnaire was developed to include patient-reported outcome (PRO) items that can be administered as a daily diary in the study. Overall activity score ranges from 0 to 240 and general physical activity score ranges from 0 to 4. Higher scores indicate more favorable states.	At Day 9 and Day 77
Secondary	Quality of Life as Measured With the PRO - Change in Activities and Symptoms	REALIsM-HF exploratory daily questionnaire was developed to include patient-reported outcome (PRO) items that can be administered as a daily diary in the study. Answers to question "How have your physical activities changed since you were discharged from the hospital": 1= Very much more physically active; 2= Much more physically active; 3= A little more physically active; 4= No change in physical activities; 5= A little less physically active; 6= Much less physically active; 7= Very much less physically active. Answers to questions "How has your feeling of tiredness changed since you were discharged from the hospital", "How has your shortness of breath changed since you were discharged from the hospital" and "How has your swelling in your legs, ankles, or feet changed since you were discharged from the hospital": 1= Very much improved; 2= Much improved; 3= Minimally improved; 4= No change; 5= Minimally worse; 6= Much worse; 7= Very much worse.	At Day 9 and Day 77
Secondary	Copeptin	Blood sample for biomarkers including Copeptin were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls.	At Day 9 and Day 84
Secondary	Galectin-3	Blood sample for biomarkers including Galectin-3 were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls.	At Day 9 and Day 84
Secondary	Growth Differentiation Factor 15 (GDF 15)	Blood sample for biomarkers including GDF 15 were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls.	At Day 9 and Day 84
Secondary	Human Interleukin-1 Receptor 4 / ST2 (sST2)	Blood sample for biomarkers including sST2 were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls. Values above upper limit of quantification (ULOQ) were substituted by ULOQ for the calculation of statistics (ULOQ = 80.0)	At Day 9 and Day 84
Secondary	Human Insulin-like Growth Factor Binding (IGFBP7)	Blood sample for biomarkers including IGFBP7 were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls.	At Day 9 and Day 84
Secondary	N-terminal Propeptide of BNP (NT-proBNP)	Blood sample for biomarkers including NT-proBNP were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls.	At Day 9 and Day 84
Secondary	High Sensitive Troponin T (hsTRT)	Blood sample for biomarkers including hsTRT were collected from participants in order to validate such biomarkers for clinical use in the context of heart failure. Biomarkers concentration was determined in plasma/serum by a central laboratory using validated assays platforms including appropriate quality controls. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 13.0)	At Day 9 and Day 84
Secondary	Blood Pressure	Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were collected.	At Day 9, Day 77 and Day 84
Secondary	Heart Rate	Heart rate data were collected by electrocardiogram (ECG).	At Day 9, Day 77 and Day 84
Secondary	Interventricular Septal Wall Thickness	Interventricular septal wall thickness was measured by echocardiography.	At Day 84
Secondary	Diameter of the Left Ventricle in Diastole	Diameter of the left ventricle in diastole was measured by echocardiography.	At Day 84
Secondary	Diameter of the Left Ventricle in Systole	Diameter of the left ventricle in systole was measured by echocardiography.	At Day 84
Secondary	Left Ventricular End-diastolic Volume	Left ventricular end-diastolic volume was measured by echocardiography.	At Day 84
Secondary	Left Ventricular End-systolic Volume	Left ventricular end-systolic volume was measured by echocardiography.	At Day 84
Secondary	Left Ventricular Ejection Fraction	Left ventricular ejection fraction was measured by echocardiography.	At Day 84
Secondary	Left Atrial End-systolic Volume	Left atrial end-systolic volume was measured by echocardiography.	At Day 84
Secondary	Left Atrial End Systolic Volume Index	Left atrial end systolic volume index was measured by echocardiography.	At Day 84
Secondary	Mitral Peak Velocity of Early Filling (E)	Mitral peak velocity of early filling (E) was measured by echocardiography.	At Day 84
Secondary	Mitral Peak Velocity of Late Filling (A)	Mitral peak velocity of late filling (A) was measured by echocardiography.	At Day 84
Secondary	Mitral Lateral Annulus Early Diastolic Peak Velocity	Mitral lateral annulus early diastolic peak velocity was measured by echocardiography.	At Day 84
Secondary	Mitral Septal Annulus Early Diastolic Peak Velocity	Mitral septal annulus early diastolic peak velocity was measured by echocardiography.	At Day 84
Secondary	Tricuspid Annular Plane Systolic Excursion	Tricuspid annular plane systolic excursion was measured by echocardiography.	At Day 84
Secondary	Pressure Gradient of Tricuspid Valve	Pressure gradient of tricuspid valve was measured by echocardiography.	At Day 84
Secondary	Right Atrial Mean Pressure	Right atrial mean pressure was measured by echocardiography.	At Day 84
Secondary	Heart Rate Variability (HRV) Derived From ECG	Heart rate variability (HRV) derived from ECG were measured with AVIVO MPM and VitalPatch biosensor	Up to Day 84
Secondary	Number of Participants Per NYHA Classification by Visit	The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. The Stages of Heart Failure: Class I = No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II = Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III = Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20 - 100 m). Comfortable only at rest. Class IV = Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.	At Day 9 and Day 84